VERACYTE, INC.·4

Jul 7, 5:47 PM ET

Kennedy Keith 4

4 · VERACYTE, INC. · Filed Jul 7, 2020

Insider Transaction Report

Form 4
Period: 2020-07-02
Kennedy Keith
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2020-07-02$5.98/sh+2,800$16,744158,398 total
  • Exercise/Conversion

    Common Stock

    2020-07-06$5.98/sh+10,075$60,249162,726 total
  • Exercise/Conversion

    Common Stock

    2020-07-06$9.05/sh+15,416$139,515200,309 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-07-0622,16722,223 total
    Exercise: $7.47Exp: 2026-12-05Common Stock (22,167 underlying)
  • Sale

    Common Stock

    2020-07-02$28.02/sh5,747$161,040152,651 total
  • Exercise/Conversion

    Common Stock

    2020-07-06$7.47/sh+22,167$165,587184,893 total
  • Sale

    Common Stock

    2020-07-06$28.21/sh80,677$2,276,172119,632 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-07-022,80047,092 total
    Exercise: $5.98Exp: 2028-03-01Common Stock (2,800 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-07-0610,07537,017 total
    Exercise: $5.98Exp: 2028-03-01Common Stock (10,075 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-07-0615,4164,584 total
    Exercise: $9.05Exp: 2027-03-02Common Stock (15,416 underlying)
Footnotes (6)
  • [F1]The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 11, 2020.
  • [F2]Represents weighted average sales price. Sale prices for the transactions range from $28.00 to $28.15. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F3]Represents weighted average sales price. Sale prices for the transactions range from $28.00 to $28.58. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  • [F4]The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
  • [F5]The option began to vest on December 6, 2017 and vests at a rate of 1/36th per total number of shares subject to the award each month, subject to the continuing employment of the reporting person on the vesting date.
  • [F6]The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4